Skolkovo’s ChemRar DRI Invites International Pharmaceutical Companies and Research Institutes into Cooperation in Finding Anti-Covid-19 Drug
ChemRar, an R&D institute and resident at the Skolkovo Foundation Biomedical Technologies Cluster, has created a platform to develop innovative drugs against Covid-19. The platform is now available to potential partners and the company is inviting international pharmaceutical companies and research institutes into cooperation in finding a drug for treating Covid-19.
Since the beginning of the pandemic, ChemRar RDI has been developing and conducting tests on dozens of potential antiviral drugs. The company has now expanded its anti-Covid focus and created a platform to develop innovative drugs.
The platform allows for the development of preclinical candidates from scratch in the space of a few months. Its advantages include the completeness of the proposed antiviral models and the speed it completes tasks due to its compound library, which is accessible on a same-day basis.
The platform consists of:
- A library of potential antiviral molecules (13,000 compounds);
- CPE test with SARS-CoV-2;
- Proteases assays (3CL and PLpro);
- Polymerase assay (RdRp);
- ACE2-Spike S1 assay;
- In-vivo hamster model;
- Med.Chem optimization.
Irina Tyrnova, CEO of ChemRar RDI: “The CoV in-vitro screening platform, an integrated service for identifying small molecules, will allow for the global pharmaceutical community to find approaches to discovering drugs for Covid-19. We invite into cooperation international partners interested in creating a pipeline for innovative antiviral candidates.”
Ivan Taskin, the project manager of the Skolkovo Foundation Biomedical Technologies Cluster: “Since the first days of the Covid-19 pandemic, the Skolkovo Foundation has been actively supporting companies developing solutions that include new antiviral drugs, vaccines and diagnostic methods. In 2020, the Foundation created a procedure to fast-track support for priority projects aimed at tackling the spread of Covid-19 and the consequences of the pandemic. Within the framework of this procedure, the Biomedical Technologies Cluster selected ten such projects. A number of residents’ solutions have already gained product licences and are actively being used in practical healthcare. However, the fight against this new virus is sufficiently urgent for a number of reasons, including a shortage of effective and safe preventative measures and treatment. The platform created by ChemRar RDI, which is for the development of innovative drugs, can help in supporting domestic healthcare with new medicinal drugs and, in doing so, attracting partners from abroad.”
ChemRar Group unites R&D service and startups companies in the field of innovative pharmaceuticals for the development and commercialization of novel medicines, diagnostics, preventive care and new treatments of life-threatening diseases. Website: http://en.chemrar.ru
Phone: +7 495 925 30 74 #520
The Skolkovo Foundation is a non-profit organization founded in 2010 and functions as the administrator of the Skolkovo Innovation Center. The goal of the Foundation is to support technological entrepreneurship in Russia and the commercialization of the results of research activities. The number of Skolkovo residents has already reached nearly 2,500. The Foundation provides them with an array of services that are necessary to roll out developments onto the Russian and international markets. Resident status gives a company tax and customs privileges. In 2019, residents’ revenue comprised over 100 billion rubles, and the amount of investment they raised amounted to 13 billion rubles. Since 2019, legislation has allowed any organization conducting research activities in Russia to access the services and benefits of the Skolkovo Innovation Center. Located on the Skolkovo Innovation Center territory is the Skolkovo Institute of Science and Technology (Skoltech), which is in the world’s top-100 young universities according to the Nature Index. The Innovation Center infrastructure comprises, among other things, the research centers of industrial partners and the largest Technopark in Europe. In 2019, three new partner R&D centers, which belong to Sibur, TMK, and Tatneft, opened at the innovation center. A total of 750,000 square meters of residential buildings, research and educational centers have been put into operation on Skolkovo territory, and extrabudgetary investment in infrastructure exceeded 100 billion rubles.